Active, not recruitingPHASE1, PHASE2NCT05544552
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Studying Muscular tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tyra Biosciences, Inc
- Principal Investigator
- Doug WarnerTyra Biosciences, Inc
- Intervention
- TYRA-300(drug)
- Enrollment
- 310 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (19)
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- UMass Memorial Medical Center, Worchester, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, United States
- Duke Cancer Institute (DCI) - Duke Cancer Center, Durham, North Carolina, United States
- Cleveland Clinic - Main Campus, Cleveland, Ohio, United States
- Vanderbilt University Medical Center (VUMC) - Vanderbilt-Ingram Cancer Center (VICC) - Nashville, Nashville, Tennessee, United States
- Seattle Cancer Care Alliance (SCCA) - South Lake Union, Seattle, Washington, United States
- Macquarie University, Macquarie Park, New South Wales, Australia
- Tasman Oncology, Southport, Queensland, Australia
- Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
- Austin Health, Heidelberg, Victoria, Australia
- Peter MacCallum Cancer Research Unit, Melbourne, Victoria, Australia
- Linear Clinical Research Limited, Nedlands, Washington, Australia
- Institut de Cancerologie de L'Ouest (ICO), Saint-Herblain, France
- Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05544552 on ClinicalTrials.govOther trials for Muscular tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07144319Exploration of Novel AI-enabled Blue Light Enhanced CystoscopyPhotocure
- RECRUITINGPHASE2NCT07475403Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerTianjin Medical University Second Hospital
- RECRUITINGPHASE2NCT07475806A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderAstellas Pharma Global Development, Inc.
- RECRUITINGNANCT07431788The Effect of Uterine Manipulator Use During Abdominal Hysterectomy on Postoperative Sexual FunctionErkan Gol
- RECRUITINGNANCT07339761Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention StudyUniversity of Aarhus
- RECRUITINGPHASE2NCT07363057A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer SurvivorsGI Innovation, Inc.
- RECRUITINGPHASE3NCT06919965A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder CancerJanssen Research & Development, LLC
- ACTIVE NOT RECRUITINGNANCT07001670Investigation of the Effects of Tele-Yoga Training in Individuals With Lung Cancer Undergoing Lung Resection SurgeryIstanbul University